Jacek Myszko speaking at the 2019 Medicines for Europe Legal Affairs Conference

Jesteśmy kancelarią, którą tworzą ludzie 
o ogromnej pasji, wiedzy i doświadczeniu. Nasz zespół stale się powiększa.

Kancelaria Sołtysiński Kawecki & Szlęzak specjalizuje się w wielu branżach, w tym w prawie cywilnym, handlowym oraz administracyjnym. Oferują wsparcie w sprawach dotyczących fuzji i przejęć, a także w kwestiach związanych z ochroną danych osobowych. Ich doświadczenie obejmuje również doradztwo w zakresie prawa pracy oraz sporów sądowych, co czyni ich wszechstronnym partnerem dla klientów z różnych sektorów.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Prawo spółek, fuzje i przejęcia
Showing 0 of 100
No results found.
There are no results with this criteria. Try changing your search.
News
14.03.2019
Jacek Myszko speaking at the 2019 Medicines for Europe Legal Affairs Conference

The 2019 Medicines for Europe Legal Affairs Conference will take place between 26-27 March 2019, for the first time, in Amsterdam. SK&S is pleased to announce that Jacek Myszko is invited as a speaker in one of the panels: “What’s new on Biosimilars: opportunities or challenges for biosimilar medicine developers”.

In its 15th edition, this conference will provide participants with the opportunity to exchange views and share ideas with leading industry executives and experts, counsel and European institution officials around the latest developments in intellectual property and legal affairs concerning generic, biosimilar and value added medicines within Europe and worldwide.

The conference will address:

  • A General Counsel discussion on international developments around IP and competition
  • What to expect from the pharma incentives review and from the Supplementary Protection Certificate (SPC) Regulation
  • The SPC Manufacturing Waiver: what conclusions can be drawn?
  • Brexit: the IP landscape and business strategies for the sector
  • What’s new on Biosimilars: opportunities or challenges for biosimilar medicine developers?
  • The latest developments at the European Patent Office

For more details on the Conference please follow the link.